Editorial on Nutrition
Is sarcopenia a prognostic factor after living donor liver transplantation? Akira Umemura, Takeshi Takahara, Hiroyuki Nitta, Yasushi Hasegawa, Akira Sasaki Department of Surgery, Iwate Medical University, Morioka, Japan Correspondence to: Akira Umemura. Department of Surgery, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan. Email: [email protected]. Provenance: This is an invited Editorial commissioned by Editor-in-Chief Yilei Mao (Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China). Comment on: Kaido T, Tamai Y, Hamaguchi Y, et al. Effects of pretransplant sarcopenia and sequential changes in sarcopenic parameters after living donor liver transplantation. Nutrition 2017;33:195-8. Submitted Feb 21, 2017. Accepted for publication Mar 23, 2017. doi: 10.21037/hbsn.2017.03.13 View this article at: http://dx.doi.org/10.21037/hbsn.2017.03.13
We read with great interest the article by Kaido et al. (1) entitled “Effects of Pretransplant Sarcopenia and Sequential Changes in Sarcopenic Parameters after Living Donor Liver Transplantation,” published in the journal Nutrition. The authors previously reported that the preoperative skeletal muscle mass (SMM) was significantly correlated with the branched-chain amino acid (BCAA) to tyrosine ratio and the body cell mass (2). They also found that a low preoperative SMM was an independent risk factor for mortality after a living donor liver transplantation (LDLT) (2). Therefore, they conducted this prospective clinical study to investigate the effects of pretransplant sarcopenia on survival, and to examine any sequential changes in the sarcopenic parameters after an LDLT. In this article, sarcopenia was defined by measuring the SMM and grip strength (GS). The overall survival rates after an LDLT were significantly lower in those patients with sarcopenia than in those without sarcopenia (P
Is sarcopenia a prognostic factor after living donor liver transplantation? Akira Umemura, Takeshi Takahara, Hiroyuki Nitta, Yasushi Hasegawa, Akira Sasaki Department of Surgery, Iwate Medical University, Morioka, Japan Correspondence to: Akira Umemura. Department of Surgery, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan. Email: [email protected]. Provenance: This is an invited Editorial commissioned by Editor-in-Chief Yilei Mao (Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China). Comment on: Kaido T, Tamai Y, Hamaguchi Y, et al. Effects of pretransplant sarcopenia and sequential changes in sarcopenic parameters after living donor liver transplantation. Nutrition 2017;33:195-8. Submitted Feb 21, 2017. Accepted for publication Mar 23, 2017. doi: 10.21037/hbsn.2017.03.13 View this article at: http://dx.doi.org/10.21037/hbsn.2017.03.13
We read with great interest the article by Kaido et al. (1) entitled “Effects of Pretransplant Sarcopenia and Sequential Changes in Sarcopenic Parameters after Living Donor Liver Transplantation,” published in the journal Nutrition. The authors previously reported that the preoperative skeletal muscle mass (SMM) was significantly correlated with the branched-chain amino acid (BCAA) to tyrosine ratio and the body cell mass (2). They also found that a low preoperative SMM was an independent risk factor for mortality after a living donor liver transplantation (LDLT) (2). Therefore, they conducted this prospective clinical study to investigate the effects of pretransplant sarcopenia on survival, and to examine any sequential changes in the sarcopenic parameters after an LDLT. In this article, sarcopenia was defined by measuring the SMM and grip strength (GS). The overall survival rates after an LDLT were significantly lower in those patients with sarcopenia than in those without sarcopenia (P
